Keyword Analysis & Research: keynote 407

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
keynote 4070.420.559561011
keynote1.210.84286217
4070.620.38362203

Keyword Research: People who searched keynote 407 also searched

Keyword CPC PCC Volume Score
keynote 4071.450.5831793
keynote 407 nejm0.810.6736889
keynote 407 5 year update1.550.9630873
keynote 407 update0.60.1400779
keynote 407 trial0.850.9261195
keynote 407 orr0.550.263271
keynote 407 results1.790.162635
keynote 407 5 year1.680.2250028
keynote 407 pfs20.4894738
keynote 407 asco1.080.1631219
keynote 407 protocol0.920.5312291
keynote 407 esmo 20220.860.569702
keynote 407 2 year update1.260.3926684
keynote 407 clinical trial0.520.7393230

Search Results related to keynote 407 on Search Engine

  • Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lu…

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMoa1810865

    WebSep 25, 2018 · , for the KEYNOTE-407 Investigators * Author Info & Affiliations. Published September 25, 2018. N Engl …

    DA: 77 PA: 33 MOZ Rank: 4

  • Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/36735893/

    WebApr 10, 2023 · We report 5-year efficacy and safety outcomes from the phase III KEYNOTE-407 study (ClinicalTrials.gov identifier: NCT02775435). Eligible …

    DA: 23 PA: 35 MOZ Rank: 53

  • Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lun…

    ascopubs.org

    https://ascopubs.org/doi/10.1200/JCO.22.01990

    WebThis exploratory analysis of the phase III KEYNOTE-407 study evaluated whether patients with previously untreated, metastatic squamous non–small-cell …

    DA: 28 PA: 92 MOZ Rank: 31

  • A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus ... - P…

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/32599071/

    WebIntroduction: In the randomized KEYNOTE-407 study (ClinicalTrials.gov, NCT02775435), pembrolizumab plus carboplatin and paclitaxel/nab …

    DA: 15 PA: 2 MOZ Rank: 18

  • KEYNOTE-407: changing the way we treat stage IV squamous non-smal…

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082291/

    WebJan 12, 2020 · KEYNOTE-407 investigated a maximum of 2 years of pembrolizumab therapy in combination with 4 cycles of carboplatin plus taxane. However, …

    DA: 35 PA: 31 MOZ Rank: 53